Figure 2.1. Survey Results: Outlook for the HIV R&D Market

Figure 4.1. Survey Results: Federal Biodefense Incentives and Decision-Making

Figure 4.2. Survey Results: New Legislation and Decision-Making

Figure 4.3. Survey Results: Modes of Collaboration

 Table 1.1. Rank Order of Deaths for the 20 Leading Causes Worldwide, Both in 2002 and in the Future (2030)

Table 1.2. Select List of the More than Two Dozen Human Pathogens Newly Recognized in the Past Few Decades

Table 1.3. Chronic Conditions Associated with Infectious Disease Agents

Table 2.1. Brand-Name Drugs Approved by the U.S. FDA for Use in the Treatment of HIV Infection

Table 2.2. HIV Antiretrovirals in Development

Table 2.3. Select List of Companies Involved in Bacteriophage R&D and the Nature of Their Involvement

Table 2.4. Confirmed Avian Influenza A Outbreaks in Humans since 1997

Table 2.5. Major Infectious Diseases without Controllable Vaccines

Table 2.6. New Vaccine Targets

Table 3.1. Targets of the Top-Selling Infectious Disease Molecular Diagnostic Products

Table 3.2. Cumulative Number of Laboratory-Confirmed Human Cases of Avian Influenza A H5N1 Reported to WHO

Table 3.3. Commercially Available Influenza Rapid Diagnostic Tests

Table 4.1. Generic Antiretroviral Manufacturers in the United States

Table 4.2. Prevalence of Drug Resistance among Some of the More Common Bacterial Human Pathogens

Table 4.3. Total U.S. Federal Government R&D Expenditures by Recipient

Table 4.4. Total U.S. Federal Government Development Expenditures by Recipient

Table 4.5. Projected Trends in Global Years of Life Lost (YLL) per 1,000 (Population Size)

Table 4.6. Proportional Contribution to Total Disease Burden for the 20 Leading Causes of DALYs, Both Now and as Projected in 2030

Table 4.7. Ten Leading Causes of Death, by Income Group, 2030